Ramsay Health Care shares rebound 15% in June: Can they keep going?

Find out what the experts tip for the ASX healthcare shares next.

Ramsay Health Care Ltd (ASX: RHC) shares have climbed higher into the green on Thursday morning.

At the time of writing, the ASX healthcare shares are up around 1% and changing hands at $41.62 a piece.

Today's increase comes off the back of a 3.5% price hike yesterday.

The latest share price increase means Ramsay Health Care shares have now recovered around 15% from a dip in early June and are around 20% higher year to date. Over the past year, the shares have risen 17%.

Group of doctors celebrate by pumping fists in the air.

Image source: Getty Images

What happened to Ramsay Health Care shares?

Ramsay Health Care is one of the largest private healthcare providers in the world, with around 500 facilities across 11 countries. Its operations cover Australia, Europe, the UK, and Asia. 

The company faced several headwinds in 2025, including depressed earnings, market volatility, and ongoing cost pressures.

The ASX healthcare sector overall was under immense pressure throughout late 2025 and into early 2026, as macroeconomic pressures, rising inflation, higher cost of living, and regulatory uncertainty drove a sector-wide share price downturn.

Why are the ASX healthcare shares now rebounding?

There hasn't been any price-sensitive news out of Ramsay Health Care shares to explain the share price turnaround in June.

It's likely the result of an overall ASX healthcare sector recovery, as investors rotated back into heavily discounted healthcare names and sentiment improved following the company's latest earnings results.

The recovery has also been supported by a turnaround in the company's finances. Ramsay Health Care posted its first-half FY26 results in February, where it confirmed underlying EBIT had grown 7.3%, underlying NPAT was up 8.1%, and its Australian hospital revenue was 8.2% higher. The company's shares spiked by more than 10% on the day of the results.

The stronger half-year result seems to have helped investor sentiment shift from concerns about cost pressures and volatility towards a recovery story.

To me, it looks like investors are still snapping up the shares while they're trading for cheap.

Can Ramsay Health Care shares keep climbing higher? Here's what the experts think

Analysts and brokers are divided about the outlook for Ramsay Health Care shares over the next 12 months.

Market Index data shows brokers are split between a buy and a sell rating. The average $40.60 target price, however, implies a potential 3% downside at the time of writing.

On TradingView data, sentiment is also split. Out of 12 analysts, seven have a hold rating on the healthcare stock. Another four rate the shares as a buy or strong buy, and one has a strong sell stance.

The average $41.30 target price implies a downside of around 1% at the time of writing. But some expect the shares to jump 13% higher to $47.17, and others tip the stock to crash 20% back down to $32.90 a piece.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »